The Lung Cancer Centre of Excellence Conference 2017
Professor Caroline Dive
Title: Joint Centre Lead for the CRUK Lung Cancer Centre of Excellence
Organisation: Manchester University
Caroline is Deputy Director of the Cancer Research UK Manchester Institute and leads the Clinical and Experimental Pharmacology Group at the Institute. She is Joint Centre Lead for the recently established CRUK Lung Cancer Centre of Excellence at Manchester and UCL, with Professor Charles Swanton at UCL.
Caroline’s research has a strong focus on circulating tumour cells (CTCs), particularly in lung cancer; where she has recently developed unique xenotransplantation models using CTCs enriched from small cell lung cancer patients’ blood samples, providing a fully tractable system for therapy testing and understanding drug resistance mechanisms.
Caroline is heavily involved with the CRUK-funded TRACERx consortium (led by Prof Charles Swanton), a pioneering study of intratumoural heterogeneity and evolution of non-small cell lung cancer, where she directs the CTC analysis within the consortium.
Professor Charles Swanton
Title: Joint Centre Lead for the CRUK Lung Cancer Centre of Excellence
Organisation: UCL Cancer Institute, London
Charles completed his MDPhD in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician/scientist medical oncology training in 2008. Charles combines his laboratory research at the Francis Crick Institute with clinical duties focussed on biological mechanisms of cancer drug resistance. Charles was made Fellow of the Royal College of Physicians in April 2011 and Chair in Personalised Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011. Charles is the Chief Investigator of the CRUK TRACERx lung cancer evolution study and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013, Fellow of the European Academy of Cancer Sciences in 2013, and Fellow of the Academy of Medical Sciences in 2015. Charles was awarded the Jeremy Jass Prize (2014), Stand up to Cancer Translational Cancer Research Prize (2015), Glaxo Smithkline Biochemical Society Prize in recognition of distinguished research leading to new advances in medical science and the Ellison-Cliffe Medal and Lecture, Royal Society of Medicine (2016). Charles was appointed Napier Professor in Cancer by the Royal Society in 2016.
Title: Associate Professor
Organisation: Helen Diller Family Comprehensive Cancer Centre
Trever completed his MD and PhD at NYU School of Medicine, before moving to the Brigham and Women’s Hospital/Harvard and then Memorial Sloan Kettering Cancer Centre for advanced training. He’s now based at the University of California at San Francisco, Helen Diller Family Comprehensive Cancer Centre, where he is an Associate Professor, and has been since 2011.
The goal of his research is to improve precision medicine strategies for lung cancer patients – in particular, to understand mechanisms of resistance to targeted treatments, and to design new strategies to overcome it. His multidisciplinary team is guided by the ‘bench-to-bedside’ philosophy – combining functional genomics with clinical datasets and pharmacological approaches to reveal key signalling pathways driving drug resistance.
Trever has pioneered the idea of rational upfront combination therapies (polytherapies) that target the driver oncoprotein together with the pathway most likely to drive resistance. This work has provided the scientific rationale for several innovative clinical trials aimed at improving the efficacy of lung cancer treatments for patients. Trever Bivona website
Professor Sam Janes
Organisation: University College London Hospitals
Sam won an MRC Training Fellowship to perform a PhD and then a post-doctoral period working in the CRUK Lincoln’s Inn Fields Institute with Fiona Watt working on integrin adhesion molecules and cancer cell survival. He then moved as an MRC Clinician Scientist to UCL leading a group interested in the role of stem cells in lung cancer pathogenesis and treatment of lung disease using cell therapies. He was awarded a Wellcome Trust Senior Clinical Fellowship in October 2010 to work on novel cell therapies for lung cancers resulting in a DPFS first–in–man award and recently won his Wellcome Senior Fellowship renewal to study lung cancer pathogenesis.
He works as a consultant at UCLH with a particular interest in Lung Cancer, mesothelioma, interventional and diagnostic bronchoscopy and early lung cancer detection. He is Head of Respiratory Research Department at UCL and director of the Lung Cancer Board for London Cancer.
Professor Tyler Jacks
Title: Director of the Koch Institute for Integrative Cancer Research
Organisation: Massachusetts Institute of Technology
Tyler Jacks, PhD is the Director of the Koch Institute for Integrative Cancer Research at MIT, the David H. Koch Professor of Biology, and an Investigator of the Howard Hughes Medical Institute, and a Daniel K. Ludwig Scholar. Over the course of his career at MIT, Professor Jacks has pioneered the use of gene targeting technology to study cancer-associated genes and to construct models of many human cancer types, including cancers of the lung, brain, and ovary. His laboratory has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment. Professor Jacks has published more than 200 scientific papers.
Professor Jacks has served on the Board of Scientific Advisors of the National Cancer Institute, is the immediate past chair of the National Cancer Advisory Board, and served as co-chair of Vice President Biden’s Cancer Moonshot’s Blue Ribbon Panel. He is an advisor to several biotechnology and pharmaceutical companies, and is a director of Amgen and Thermo Fisher Scientific. Among many honors, Professor Jacks is a member of the National Academy of Sciences, the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences, and the Fellows of the American Association of Cancer Research Academy
Dr Avrum Spira
Title: Associate Professor
Organisation: Boston University School of Medicine
Dr. Spira is an Associate Professor in the Departments of Medicine, and Pathology and Bioinformatics and is Chief of the Division of Computational Biomedicine in the Department of Medicine at BUSM. He attends in the Medical Intensive Care Unit at Boston Medical Center. He directs the Bioinformatics Program in the Pulmonary Center and directs the Translational Bioinformatics Program in the Clinical and Translational Science Institute at Boston University.
Dr. Spira’s laboratory research interests focus on applying genomic and bioinformatics tools to the translational study of lung cancer and Chronic Obstructive Lung Disease (COPD), with the ultimate objective of developing novel diagnostics and therapeutics that can directly impact clinical care. He is funded as a Principal Investigator through three institutes at the NIH including the NCI, NHLBI, and NIEHS as well as the Department of Defense. His research program centers around the concept that inhaled toxins create a “field of injury” in all exposed airway epithelial cells, and that by measuring gene expression in a relatively pure population of these cells, one can develop a gene-expression profile that reflects the physiological response to and damage from the toxin. The importance of the “field-of-injury” concept is that it allows for the detection of lung disease in tissues that are more readily assayed than the diseased lung itself.
Professor Julian Sage
Organisation: Stanford University
Dr. Sage's research program focuses on the mechanisms that control the proliferation of mammalian cells under normal and pathological conditions (regeneration, cancer), with a particular emphasis on stem cells and gene regulatory networks. They combine genetic, genomics, and proteomics approaches to identify and investigate genes and pathways involved in cancer initiation and progression. The lab uses genome-editing strategies to develop and study genetically-engineered mouse models for human cancers, including lung cancer, pancreatic cancer, and liver cancer. Their work spans the investigation of fundamental biological processes to the implementation of clinical trials based on our findings in pre-clinical models.
Professor Enriqueta Felip
Title: Head of the Thoracic Cancer and the Head and Neck Cancer Units
Organisation: Vall d'Hebron University Hospital
Professor Enriqueta Felip is Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d'Hebron University Hospital, Barcelona, Spain. She is also Associate Professor at the Autonomous University of Barcelona (UAB). Enriqueta Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology.
Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. Current research lines include the individualization of chemotherapy in early-stage disease, the use of pharmacogenomic approaches, the evaluation of new drugs, and the optimization of immunotherapy strategies.
She is currently a member of the Spanish Lung Cancer Group (SLCG), the Spanish Society of Medical Oncology (SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the National Lung Cancer Partnership. She is the coordinator of the lung cancer program of the European School of Oncology (ESO). Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.
Professor Henricus J de Koning
Title: Professor of Public Health & Screening Evaluation
Organisation: Erasmus Medical Center
Professor Henricus (Harry) J de Koning worked as Researcher and Assistant Professor in the Department of Public Health of the Erasmus University in Rotterdam (1987-1999). He became Associate Professor in 1999 and in 2008 he was appointed Professor of Public Health & Screening Evaluation in the same department. He was also Senior Associate in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health (2011-2012). Since 2011 he has been a Member of the Medical Advisory Board of the Royal Netherlands Academy of Arts and Sciences (KNAW).
His major scientific contributions are in the areas of:
- Designing, running and evaluating large-scale multidisciplinary population-based randomized controlled screening trials to establish the efficacy of screening;
- Evaluating active international screening programs and tests to establish effectiveness;
- Guiding public health policies using predictions of favorable and unfavorable effects and the cost of screening, based on micro-simulation modelling of the natural history of disease, and cost-effectiveness and cost-utility analyses.
If you need more information on the event please contact us: